CTSO - Cytosorbents Crp logo

Cytosorbents Crp

CTSO

Cytosorbents Corporation develops and commercializes blood purification medical devices, including CytoSorb for massive inflammation and organ failure, VetResQ for animals, and PuriFi, an advanced hemoperfusion pump.

⚕️ Healthcare NASDAQ Listed 2013 $ USD
$1,000 invested 20 years ago →$8today

Score Overview

1 Year
Score
Net Growth-122.16%
Net TrendShrank
Net Income Consistency—
Rev Growth0.41%
Rev TrendGrew
Revenue Consistency—
5 Years
Score5.1
Net Growth25.84%
Net Trend60%
Net Income Consistency—
Rev Growth-7.21%
Rev Trend60%
Revenue Consistency—
10 Years
Score
Net Growth-52.55%
Net Trend50%
Net Income Consistency
Rev Growth353.52%
Rev Trend80%
Revenue Consistency
All Time
Score
Net Growth-289.35%
Net Trend46%
Net Income Consistency
Rev Growth45x
Rev Trend85%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Cytosorbents Crp has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. CTSO does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 6.01—
1 Year2025-10-22
$ 17.00-64.65%
5 Years2021-10-22
$ 116.60-94.85%
10 Years2016-10-21
$ 113.00-94.68%
20 Years2006-10-20
$ 735.00-99.18%
All Time2013-11-07
$ 60.50-90.07%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 37M-$ 18M$ 4M
2025$ 37M-$ 8M$ 6M
2024$ 35M-$ 20M$ 3M
2023$ 31M-$ 29M$ 14M
2022$ 34M-$ 32M$ 22M
2021$ 40M-$ 24M$ 52M
2020$ 39M-$ 7M$ 71M
2019$ 22M-$ 19M$ 12M
2018$ 20M-$ 17M$ 22M
2017$ 13M-$ 8M$ 17M
2016$ 8M-$ 11M$ 5M
2015$ 4M-$ 8M$ 7M
2014$ 3M-$ 9M$ 5M
IPO2013$ 821.79K-$ 4M$ 2M
CTSO - Cytosorbents Crp logo

Cytosorbents Crp fundamental performance

Between 2020 and 2025, revenue declined from $ 39M to $ 37M and net income went from -$ 7M to -$ 8M. Revenue increased in 3 of those 5 years; net income in 3.

Across Cytosorbents Crp's full reported history, from 2013 to 2025, revenue grew from $ 821.79K to $ 37M and net income went from -$ 4M to -$ 8M. Revenue increased in 85% of the years measured; net income in 46%.

Cytosorbents Crp currently holds a 5-year HDB Score of 5.1 out of 10. How the HDB Score is calculated.

Membership

Explore CTSO with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies